A European, Randomised, Double-blind, Active Comparator Controlled, Cross-over, Efficacy and Safety Study of a New 10% Ready To-use Liquid Human Intravenous Immunoglobulin (I10E) Versus Kiovig in Patients With Multifocal Motor Neuropathy
Phase of Trial: Phase III
Latest Information Update: 13 Jun 2019
Price : $35 *
At a glance
- Drugs Immune globulin (Primary)
- Indications Multifocal motor neuropathy
- Focus Registrational; Therapeutic Use
- Acronyms LIME
- Sponsors LFB Biotechnologies
- 07 Aug 2016 This trial is completed in spain.
- 18 Jul 2016 Status changed from active, no longer recruiting to completed.
- 11 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.